KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) EBITDA Margin: 2010-2025

Historic EBITDA Margin for Nektar Therapeutics (NKTR) over the last 16 years, with Sep 2025 value amounting to -268.63%.

  • Nektar Therapeutics' EBITDA Margin fell 12627.00% to -268.63% in Q3 2025 from the same period last year, while for Sep 2025 it was -156.69%, marking a year-over-year increase of 764.00%. This contributed to the annual value of -106.88% for FY2024, which is 18571.00% up from last year.
  • Latest data reveals that Nektar Therapeutics reported EBITDA Margin of -268.63% as of Q3 2025, which was up 17.14% from -324.21% recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' EBITDA Margin ranged from a high of 49.18% in Q4 2024 and a low of -708.07% during Q2 2022.
  • Its 3-year average for EBITDA Margin is -244.02%, with a median of -211.90% in 2024.
  • Its EBITDA Margin has fluctuated over the past 5 years, first slumped by 31,906bps in 2022, then spiked by 46,123bps in 2023.
  • Nektar Therapeutics' EBITDA Margin (Quarterly) stood at -451.48% in 2021, then surged by 21,323bps to -238.25% in 2022, then soared by 9,794bps to -140.30% in 2023, then soared by 18,948bps to 49.18% in 2024, then tumbled by 12,627bps to -268.63% in 2025.
  • Its EBITDA Margin was -268.63% in Q3 2025, compared to -324.21% in Q2 2025 and -425.76% in Q1 2025.